{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:50Z","timestamp":1791559430392,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"DOI":"10.7759\/cureus.113285","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:38:56Z","timestamp":1784893136000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Pulmonary Differentiation Syndrome Despite Corticosteroid Prophylaxis in Acute Promyelocytic Leukemia: Clinical Improvement With Pulse Methylprednisolone Therapy and High-Flow Nasal Cannula"],"prefix":"10.7759","author":[{"given":"Paul","family":"Cardozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthia","family":"Berrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Favio","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz MA","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, et al.. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019, 133:1630-43. 10.1182\/blood-2019-01-894980","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco F","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al.. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013, 369:111-21. 10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \"retinoic acid syndrome\" in acute promyelocytic leukemia","volume":"117","author":"Frankel SR","year":"1992","unstructured":"Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The \"retinoic acid syndrome\" in acute promyelocytic leukemia. Ann Intern Med. 1992, 117:292-6. 10.7326\/0003-4819-117-4-292","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1062524","article-title":"The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions","volume":"12","author":"Iyer SG","year":"2022","unstructured":"Iyer SG, Elias L, Stanchina M, Watts J. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Front Oncol. 2022, 12:1062524. 10.3389\/fonc.2022.1062524","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz MA","year":"2014","unstructured":"Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014, 123:2777-82. 10.1182\/blood-2013-10-512640","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl M","year":"2019","unstructured":"Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019, 187:157-62. 10.1111\/bjh.16151","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194767","article-title":"Differentiation syndrome in acute leukemia: APL and beyond","volume":"15","author":"Woods AC","year":"2023","unstructured":"Woods AC, Norsworthy KJ. Differentiation syndrome in acute leukemia: APL and beyond. Cancers (Basel). 2023, 15:4767. 10.3390\/cancers15194767","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi AT","year":"2021","unstructured":"Fathi AT, Stein EM, DiNardo CD, Levis MJ, Montesinos P, de Botton S. Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. Am J Hematol. 2021, 96:735-46. 10.1002\/ajh.26142","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s1521-6926(03)00065-3","article-title":"The epidemiology of acute promyelocytic leukaemia","volume":"16","author":"Douer D","year":"2003","unstructured":"Douer D. The epidemiology of acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003, 16:357-67. 10.1016\/s1521-6926(03)00065-3","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos P","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, et al.. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009, 113:775-83. 10.1182\/blood-2008-07-168617","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19763","article-title":"Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia","volume":"205","author":"Yanada M","year":"2024","unstructured":"Yanada M. Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia. Br J Haematol. 2024, 205:1672-3. 10.1111\/bjh.19763","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046458","article-title":"Analysis of risk factors for differentiation syndrome in patients with acute promyelocytic leukemia","volume":"104","author":"Zhang M","year":"2025","unstructured":"Zhang M, He H, Ye Y, Guo Z. Analysis of risk factors for differentiation syndrome in patients with acute promyelocytic leukemia. Medicine (Baltimore). 2025, 104:e46458. 10.1097\/MD.0000000000046458","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I treat hyperleukocytosis in acute myeloid leukemia","volume":"125","author":"R\u00f6llig C","year":"2015","unstructured":"R\u00f6llig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015, 125:3246-52. 10.1182\/blood-2014-10-551507","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.14282","article-title":"Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: the HIGH randomized clinical trial","volume":"320","author":"Azoulay E","year":"2018","unstructured":"Azoulay E, Lemiale V, Mokart D, et al.. Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: the HIGH randomized clinical trial. JAMA. 2018, 320:2099-107. 10.1001\/jama.2018.14282","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04824-9","article-title":"High-flow nasal cannula oxygen in patients with haematological malignancy: a retrospective observational study","volume":"101","author":"Tetlow S","year":"2022","unstructured":"Tetlow S, Anandanadesan R, Taheri L, Pagkalidou E, De Lavallade H, Metaxa V. High-flow nasal cannula oxygen in patients with haematological malignancy: a retrospective observational study. Ann Hematol. 2022, 101:1191-9. 10.1007\/s00277-022-04824-9","journal-title":"Ann Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510331-severe-pulmonary-differentiation-syndrome-despite-corticosteroid-prophylaxis-in-acute-promyelocytic-leukemia-clinical-improvement-with-pulse-methylprednisolone-therapy-and-high-flow-nasal-cannula","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:38:56Z","timestamp":1784893136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510331-severe-pulmonary-differentiation-syndrome-despite-corticosteroid-prophylaxis-in-acute-promyelocytic-leukemia-clinical-improvement-with-pulse-methylprednisolone-therapy-and-high-flow-nasal-cannula"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.113285","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}